245 related articles for article (PubMed ID: 19622344)
1. beta-Sheet-breaking peptides inhibit the fibrillation of human alpha-synuclein.
Kim YS; Lim D; Kim JY; Kang SJ; Kim YH; Im H
Biochem Biophys Res Commun; 2009 Oct; 387(4):682-7. PubMed ID: 19622344
[TBL] [Abstract][Full Text] [Related]
2. The hexapeptide PGVTAV suppresses neurotoxicity of human α-synuclein aggregates.
Choi MY; Kim YS; Lim D; Kang SJ; Kim YH; Lee K; Im H
Biochem Biophys Res Commun; 2011 May; 408(2):334-8. PubMed ID: 21510923
[TBL] [Abstract][Full Text] [Related]
3. Aggregation-defective alpha-synuclein mutants inhibit the fibrillation of Parkinson's disease-linked alpha-synuclein variants.
Koo HJ; Choi MY; Im H
Biochem Biophys Res Commun; 2009 Aug; 386(1):165-9. PubMed ID: 19501571
[TBL] [Abstract][Full Text] [Related]
4. A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders.
El-Agnaf OM; Paleologou KE; Greer B; Abogrein AM; King JE; Salem SA; Fullwood NJ; Benson FE; Hewitt R; Ford KJ; Martin FL; Harriott P; Cookson MR; Allsop D
FASEB J; 2004 Aug; 18(11):1315-7. PubMed ID: 15180968
[TBL] [Abstract][Full Text] [Related]
5. Altered ion channel formation by the Parkinson's-disease-linked E46K mutant of alpha-synuclein is corrected by GM3 but not by GM1 gangliosides.
Di Pasquale E; Fantini J; Chahinian H; Maresca M; Taïeb N; Yahi N
J Mol Biol; 2010 Mar; 397(1):202-18. PubMed ID: 20114052
[TBL] [Abstract][Full Text] [Related]
6. Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson's disease.
Azeredo da Silveira S; Schneider BL; Cifuentes-Diaz C; Sage D; Abbas-Terki T; Iwatsubo T; Unser M; Aebischer P
Hum Mol Genet; 2009 Mar; 18(5):872-87. PubMed ID: 19074459
[TBL] [Abstract][Full Text] [Related]
7. Association of alpha-synuclein and mutants with lipid membranes: spin-label ESR and polarized IR.
Ramakrishnan M; Jensen PH; Marsh D
Biochemistry; 2006 Mar; 45(10):3386-95. PubMed ID: 16519533
[TBL] [Abstract][Full Text] [Related]
8. Role of different regions of alpha-synuclein in the assembly of fibrils.
Qin Z; Hu D; Han S; Hong DP; Fink AL
Biochemistry; 2007 Nov; 46(46):13322-30. PubMed ID: 17963364
[TBL] [Abstract][Full Text] [Related]
9. Solid-state NMR reveals structural differences between fibrils of wild-type and disease-related A53T mutant alpha-synuclein.
Heise H; Celej MS; Becker S; Riedel D; Pelah A; Kumar A; Jovin TM; Baldus M
J Mol Biol; 2008 Jul; 380(3):444-50. PubMed ID: 18539297
[TBL] [Abstract][Full Text] [Related]
10. Sequence determinants regulating fibrillation of human alpha-synuclein.
Koo HJ; Lee HJ; Im H
Biochem Biophys Res Commun; 2008 Apr; 368(3):772-8. PubMed ID: 18261982
[TBL] [Abstract][Full Text] [Related]
11. Observation of multiple intermediates in alpha-synuclein fibril formation by singular value decomposition analysis.
Kamiyoshihara T; Kojima M; Uéda K; Tashiro M; Shimotakahara S
Biochem Biophys Res Commun; 2007 Apr; 355(2):398-403. PubMed ID: 17300751
[TBL] [Abstract][Full Text] [Related]
12. PAMAM dendrimers as potential agents against fibrillation of alpha-synuclein, a Parkinson's disease-related protein.
Rekas A; Lo V; Gadd GE; Cappai R; Yun SI
Macromol Biosci; 2009 Mar; 9(3):230-8. PubMed ID: 19116892
[TBL] [Abstract][Full Text] [Related]
13. Modulation of α-synuclein fibrillization by ring-fused 2-pyridones: templation and inhibition involve oligomers with different structure.
Horvath I; Sellstedt M; Weise C; Nordvall LM; Krishna Prasad G; Olofsson A; Larsson G; Almqvist F; Wittung-Stafshede P
Arch Biochem Biophys; 2013 Apr; 532(2):84-90. PubMed ID: 23399432
[TBL] [Abstract][Full Text] [Related]
14. Dopamine affects the stability, hydration, and packing of protofibrils and fibrils of the wild type and variants of alpha-synuclein.
Follmer C; Romão L; Einsiedler CM; Porto TC; Lara FA; Moncores M; Weissmüller G; Lashuel HA; Lansbury P; Neto VM; Silva JL; Foguel D
Biochemistry; 2007 Jan; 46(2):472-82. PubMed ID: 17209557
[TBL] [Abstract][Full Text] [Related]
15. SDS-induced fibrillation of alpha-synuclein: an alternative fibrillation pathway.
Giehm L; Oliveira CL; Christiansen G; Pedersen JS; Otzen DE
J Mol Biol; 2010 Aug; 401(1):115-33. PubMed ID: 20540950
[TBL] [Abstract][Full Text] [Related]
16. Controlling aggregation propensity in A53T mutant of alpha-synuclein causing Parkinson's disease.
Kumar S; Sarkar A; Sundar D
Biochem Biophys Res Commun; 2009 Sep; 387(2):305-9. PubMed ID: 19580781
[TBL] [Abstract][Full Text] [Related]
17. Alpha-synuclein aggregation in neurodegenerative diseases and its inhibition as a potential therapeutic strategy.
Paleologou KE; Irvine GB; El-Agnaf OM
Biochem Soc Trans; 2005 Nov; 33(Pt 5):1106-10. PubMed ID: 16246056
[TBL] [Abstract][Full Text] [Related]
18. Seed-dependent accelerated fibrillation of alpha-synuclein induced by periodic ultrasonication treatment.
Kim HJ; Chatani E; Goto Y; Paik SR
J Microbiol Biotechnol; 2007 Dec; 17(12):2027-32. PubMed ID: 18167451
[TBL] [Abstract][Full Text] [Related]
19. Copper- and iron-induced differential fibril formation in alpha-synuclein: TEM study.
Bharathi ; Indi SS; Rao KS
Neurosci Lett; 2007 Sep; 424(2):78-82. PubMed ID: 17714865
[TBL] [Abstract][Full Text] [Related]
20. Anti-fibrillogenic and fibril-destabilizing activities of anti-Parkinsonian agents for alpha-synuclein fibrils in vitro.
Ono K; Hirohata M; Yamada M
J Neurosci Res; 2007 May; 85(7):1547-57. PubMed ID: 17387689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
